Jump to content

GISAID

From Wikipedia, the free encyclopedia

GISAID
Global Initiative on Sharing All Influenza Data
FormationDecember 19, 2006; 18 years ago (2006-12-19)[1][2][3][4]
TypeNonprofit organization[5]
PurposeGlobal health, research
HeadquartersMunich, Germany[6][5]
MethodDonations and grants
Key people
Websitehttps://gisaid.org

GISAID (/ˈɡɪseɪd/), the Global Initiative on Sharing All Influenza Data,[9] previously the Global Initiative on Sharing Avian Influenza Data,[10][11] is a global science initiative established in 2008 to provide access to genomic data of influenza viruses. The database was expanded to include the coronavirus responsible for the COVID-19 pandemic,[12][13] as well as other pathogens. The database has been described as "the world's largest repository of COVID-19 sequences".[14] GISAID facilitates genomic epidemiology and real-time surveillance to monitor the emergence of new COVID-19 viral strains across the planet.[15]

Since its establishment as an alternative to sharing avian influenza data[16] via conventional public-domain archives,[17] GISAID has facilitated the exchange of outbreak genome data[17] during the H1N1 pandemic[18][19] in 2009, the H7N9 epidemic[20][21] in 2013, the COVID-19 pandemic[22][23] and the 2022–2023 mpox outbreak.[24]

History

[edit]
Peter Bogner shakes hands with Robert Kloos
GISAID President Peter Bogner (l) and German State Secretary Robert Kloos [de] in Berlin, April 2010

Origin

[edit]

Since 1952, influenza strains had been collected by National Influenza Centers (NICs) and distributed through the WHO's Global Influenza Surveillance and Response System (GISRS).[25] Countries provided samples to the WHO but the data was then shared with them for free with pharmaceutical companies who could patent vaccines produced from the samples.[26] Beginning in January 2006, Italian researcher Ilaria Capua refused to upload her data to a closed database and called for genomic data on H5N1 avian influenza to be in the public domain.[27][28] At a conference of the OIE/FAO Network of Expertise on Animal Influenza, Capua persuaded participants to agree to each sequence and release data on 20 strains of influenza. Some scientists had concerns about sharing their data in case others published scientific papers using the data before them, but Capua dismissed this telling Science "What is more important? Another paper for Ilaria Capua's team or addressing a major health threat? Let's get our priorities straight."[28] Peter Bogner, a German in his 40s based in the US and who previously had no experience in public health, read an article about Capua's call and helped to found and fund GISAID.[29][30] Bogner met Nancy Cox, who was then leading the US Centers for Disease Control's influenza division at a conference, and Cox went on to chair GISAID's Scientific Advisory Council.[17]

The acronym GISAID was coined in a correspondence letter published in the journal Nature in August 2006,[30] putting forward an initial aspiration of creating a consortium for a new Global Initiative on Sharing Avian Influenza Data (later, "All" would replace "Avian"), whereby its members[17] would release data in publicly available databases up to six months after analysis and validation.[31] Initially the organisation collaborated with the Australian non-profit organization Cambia and the Creative Commons project Science Commons.[32] Although no essential ground rules for sharing were established,[33] the correspondence letter was signed by over 70 leading scientists, including seven Nobel laureates, because access to the most current genetic data for the highly pathogenic H5N1 zoonotic virus was often restricted, in part due to the hesitancy of World Health Organization member states to share their virus genomes and put ownership rights at risk.[34]

Towards the end of 2006, Indonesia announced it would not share samples of avian flu with the WHO which led to a global health crisis due to an ongoing epidemic.[26] By October 2006, Indonesia had agreed to share their data with GISAID,[35] which their health minister considered to have a "fair and transparent" mechanism for sharing data.[36] It was one of the first countries to do so.[37] In February 2007, GISAID and the Swiss Institute of Bioinformatics (SIB) announced a cooperation agreement,[17] with the SIB building and administering the EpiFlu database on behalf of GISAID.[38] Ultimately, GISAID was launched in May 2008 in Geneva on the occasion of the 61st World Health Assembly, as a registration-based database rather than a consortium.[17]

2009 onwards

[edit]

In 2009 SIB disconnected the database from the GISAID portal over a contract dispute, resulting in litigation.[38][4][39] In April 2010 the Federal Republic of Germany announced during the 7th International Ministerial Conference on Avian and Pandemic Influenza in Hanoi, Vietnam, that GISAID had entered into a cooperation agreement[40] with the German government, making Germany the long-term host of the GISAID platform.[41] Under the agreement, Germany's Federal Ministry of Food, Agriculture and Consumer Protection was to ensure the sustainability of the initiative by providing technical hosting facilities,[42] and the Federal Institute for Animal Health, the Friedrich Loeffler Institute, was to ensure the plausibility and curation of scientific data in GISAID. By 2021, the ministry was no longer involved with either database hosting nor curation.[43] In 2013 GISAID dissolved a nonprofit organisation based in Washington DC and the organisation began to be operated by a German association called Freunde von GISAID (Friends of GISAID).[29]

Some of the earliest SARS-CoV-2 genetic sequences were released by the Chinese Center for Disease Control and Prevention and shared through GISAID in mid January 2020.[44] Since 2020, millions of SARS-CoV-2 genome sequences have been uploaded to the GISAID database.[45]

In 2022, GISAID added Mpox virus[46] and Respiratory syncytial virus (RSV)[47] to the list of pathogens supported by its database. Indonesia's Ministry of Health announced in November 2023 the establishment of GISAID Academy in Bali, to focus on bioinformatics education, advance pathogen genomic surveillance, and increased regional response capacity.[48]

The GISAID model of incentivizing and recognizing those who deposit data has been recommended as a model for future initiatives;[49] Because of this work, the entity has been described as "a critical shield for humankind".[50]

Database for SARS-CoV-2 genomes

[edit]

GISAID maintains what has been described as "the world's largest repository of COVID-19 sequences",[14] and "by far the world's largest database of SARS-CoV-2 sequences".[7] By mid-April 2021, GISAID's SARS-CoV-2 database reached over 1,200,000 submissions, a testament to the hard work of researchers in over 170 different countries.[51] Only three months later, the number of uploaded SARS-CoV-2 sequences had doubled again, to over 2.4 million.[52] By late 2021, the database contained over 5 million genome sequences;[53] as of December 2021, over 6 million sequences had been submitted;[54] by April 2022, there were 10 million sequences accumulated; and in January 2023 the number had reached 14.4 million.[55]

In January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID.[56] Throughout the first year of the COVID-19 pandemic, most of the SARS-CoV-2 whole-genome sequences that were generated and shared globally were submitted through GISAID.[57] When the SARS-CoV-2 Omicron variant was detected in South Africa, by quickly uploading the sequence to GISAID, the National Institute for Communicable Diseases there was able to learn that Botswana and Hong Kong had also reported cases possessing the same gene sequence.[58]

In March 2023, GISAID temporarily suspended database access for some scientists, removing raw data relevant to investigations of the origins of SARS-CoV-2.[59][60][61] GISAID stated that they do not delete records from their database, but data may become temporarily invisible during updates or corrections.[62][63][64] Availability of the data was restored, with an additional restriction that any analysis based thereon would not be shared with the public.[65]

Governance

[edit]

The board of Friends of GISAID consists of Peter Bogner and two German lawyers who are not involved in the day-to-day operations of the organisation.[29] Scientific advice to the organization is provided by its Scientific Advisory Council, including directors of leading public health laboratories, such as WHO Collaborating Centres for Influenza.[66] In 2023, GISAID's lack of transparency was criticized by some GISAID funders, including the European Commission and the Rockefeller Foundation, with long-term funding being denied from International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).[67][68] In June 2023, it was reported in Vanity Fair that Bogner had said that "GISAID will soon launch an independent compliance board 'responsible for addressing a wide range of governance matters'".[10] The Telegraph similarly reported that GISAID's in-house counsel was developing new governance processes intended to be transparent and allow for the resolution of scientific disputes without the involvement of Bogner.[50]

Access and intellectual property

[edit]

The creation of the GISAID database was motivated in part by concerns raised by researchers from developing countries,[69] with Scientific American noting in 2009 that "a previous data-sharing system run by WHO forced them to give up intellectual property rights to their virus samples when they sent them to WHO. The virus samples would then be used by private pharmaceutical companies to make vaccines that are awarded patents and sold at a profit at prices many poor nations cannot afford".[4] In a 2022 piece in The Lancet, it was further noted that scientists in North America and Europe sought unrestricted access, with "scientists from Africa requiring sufficient protections for those who generate and share data as per the GISAID terms and conditions".[69] Unlike public-domain databases such as GenBank and EMBL, users of GISAID must have their identity confirmed and agree to a Database Access Agreement that governs the way GISAID data can be used.[50][70] These Terms of Use are "weighted in favour of the data provider and gives them enduring control over the genetic data they upload".[50] They prevent users from sharing any data with other users who have not agreed to them, and require that users of the data must credit the data generators in published work, and also make a reasonable attempt to collaborate with data generators and involve them in research and analysis that uses their data.[10][50]

A difficulty that GISAID's Data Access Agreement attempts to address is that many researchers fear sharing of influenza sequence data could facilitate its misappropriation through intellectual property claims by the vaccine industry and others, hindering access to vaccines and other items in developing countries, either through high costs or by preventing technology transfer. While most public interest experts agree with GISAID that influenza sequence data should be made public, and this is the subject of agreement by many researchers, some provide the information only after filing patent claims while others have said that access to it should be only on the condition that no patents or other intellectual property claims are filed, as was controversial with the Human Genome Project.[71] GISAID's Data Access Agreement addresses this directly to promote sharing data. GISAID's procedures additionally suggest that those who access the EpiFlu database consult the countries of origin of genetic sequences and the researchers who discovered the sequences. As a result, the GISAID license has been important in rapid pandemic preparedness.[72] However, these restrictions evidence common criticisms to an open data model.[73][74]

GISAID describes itself as "open access", which is naturally replicated by the media and in journal publications. This description indeed aligns with the original announcement of the consortium,[31] which also mentioned depositing the data to the databases participating in the INSDC. As of March 2023, this is not the case, as "GISAID does not offer a mechanism to release data to any other database".[75] A few academic papers have compared GISAID's licensing model to unrestricted, open databases,[76][72][77] highlighting the differences while other researchers have signed an open letter calling for the use of any of the INSDC's unrestricted databases.[78][79]

In 2017, GISAID's editorial board stated that "re3data.org and DataCite, the world's leading provider of digital object identifiers (DOI) for research data, affirmed the designation of access to GISAID's database and data as Open Access".[80] However, after several researchers had their accounts suspended in March 2023 as reported by the journal Science[81] and other news outlets,[82] its open access status was revoked by the Registry of Research Data Repositories (re3data), which now classifies it as a "restricted access repository".[83] In 2020 the World Health Organization chief scientist Soumya Swaminathan called the initiative "a game changer",[12] while the co-director of the European Bioinformatics Institute (EBI) Rolf Apweiler has argued that because it does not allow sequences to be reshared publicly, it hampers efforts to understand the coronavirus and the rapid rise of new variants.[78]

GISAID's restrictions on access have led to conflict with "labs and institutions whose priorities are academic rather than driven by the immediate priorities of public health protection".[50] In January 2021, GISAID's restricted access led a group of scientists to write an open letter asking for SARS-CoV-2 sequences to be deposited in open databases,[84] which was replicated in the journals Nature[73][85] and Science.[7] Furthermore, the article from Science points out that the lack of transparency in access to the database also prevents many scientists from even criticising the platform.[7] A paper from 2017 describing the success of GISAID mentions that revoking researchers' credentials was rare, but it did happen.[86] The same publication described a "perceived merit in GISAID's formula for balancing the need for control and openness". In April 2023, Science and The Economist reported these issues continue as well as the lack of transparency of its governance.[68][67] An investigation by The Telegraph into claims made by Science noted the incentives of various potential competitors in the field, for whom GISAID is an obstacle to consolidation of control over the field, and also noted that GISAID's position inevitably places it at the center of disputes between groups of scientists, which will tend to result in the losing side blaming GISAID for that outcome.[50]

See also

[edit]

References

[edit]
  1. ^ District of Columbia Corporation Registry, District of Columbia Department of Consumer and Regulatory Affairs, Initial File Number 263748
  2. ^ "OpenCorporates information for US, D.C. Company "GLOBAL INITIATIVE ON SHARING ALL INFLUENZA DATA"". opencorporates.com. Retrieved March 28, 2023.
  3. ^ a b c Greenemeier, Larry (September 14, 2009). "Open-Access Flu Research Web Site Is Relaunched Amid Controversy". Scientific American. Retrieved May 5, 2023.
  4. ^ a b c "Vereinsregister des Amtsgerichts München" [Register of associations of the district court of Munich (Germany)] (PDF). Gemeinsames Registerportal der Länder. VR 204844 (in German). Munich, Germany: Ministerium der Justiz Nordrhein-Westfalen (justice ministry of the German Land of Nordrhein-Westfalen). March 24, 2023. Retrieved March 24, 2023.
  5. ^ "GISAID - Imprint / Privacy". gisaid.org. Retrieved March 24, 2023.
  6. ^ a b c d Wadman, Meredith (March 10, 2021). "Critics decry access, transparency issues with key trove of coronavirus sequences". Science. doi:10.1126/science.abi4496. S2CID 233620925. Retrieved March 27, 2023. With more than 700,000 genomes from more than 160 countries, GISAID is by far the world's largest database of SARS-CoV-2 sequences
  7. ^ "Governance & Expertise: Scientific Advisory Council". GISAID. 2020. Retrieved July 7, 2020. The Scientific Advisory Council (SAC) advises and supports the Initiative in pursuit of its public health and scientific objectives. Its members are leading scientists with expertise in virology, microbiology, computational and molecular biology, epidemiology, evolutionary genomics and bioinformatics, and public health or animal-health..
  8. ^ Shu, Y.; McCauley, J. (March 30, 2017). "GISAID: Global initiative on sharing all influenza data – from vision to reality". Euro Surveill. 22 (13). doi:10.2807/1560-7917.ES.2017.22.13.30494. PMC 5388101. PMID 28382917.
  9. ^ a b c Eban, Katherine (June 1, 2023). "Inside the COVID Origins Raccoon Dog Cage Match". Vanity Fair.
  10. ^ Bogner, Peter; Capua, Ilaria; Lipman, David J.; Cox, Nancy J. (August 30, 2006). "A global initiative on sharing avian flu data". Nature. 442 (7106): 981. Bibcode:2006Natur.442Q.981B. doi:10.1038/442981a. S2CID 4419375.
  11. ^ a b Swaminathan, Soumya (December 17, 2020). "The WHO's chief scientist on a year of loss and learning". Nature. Retrieved December 20, 2020.
  12. ^ Korber, Bette (August 20, 2020). "Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus". Cell. 182 (4): 812–827.e19. doi:10.1016/j.cell.2020.06.043. PMC 7332439. PMID 32697968. the global sampling of SARS-CoV-2 is being very capably addressed by the Global Initiative for Sharing All Influenza Data (GISAID) database
  13. ^ a b "Hochul Extends Mask Mandate, Debuts New Surge Plan as NY Smashes Case Record Again". NBC New York. December 31, 2021. Retrieved January 13, 2022. The omicron variant... accounted for 78% of genetically sequenced positive New York COVID samples uploaded to GISAID, the world's largest repository of COVID-19 sequences, over the last two weeks.
  14. ^ Jameel, Shahid (April 2, 2020). "Coronavirus pandemic highlights key need for science and partnerships". The Telegraph (Kolkata). Retrieved December 29, 2020.
  15. ^ McDowell, Robin (May 15, 2008). "Indonesia hands over bird flu data to new database". Fox News. Associated Press. Retrieved June 7, 2020.
  16. ^ a b c d e f Elbe, Stefan; Buckland-Merrett, Gemma (January 10, 2017). "Data, disease and diplomacy: GISAID's innovative contribution to global health". Global Challenges. 1 (1): 33–46. Bibcode:2017GloCh...1...33E. doi:10.1002/gch2.1018. PMC 6607375. PMID 31565258.
  17. ^ Schnirring, Lisa (June 25, 2009). "Pandemic reveals strengths of new flu database". Center for Infectious Disease Research and Policy. Retrieved June 7, 2020.
  18. ^ "Viral gene sequences to assist update diagnostics for swine influenza A(H1N1)" (PDF). World Health Organization. April 25, 2009. Retrieved June 7, 2020.
  19. ^ "The fight against bird flu". Nature. 496 (7446): 397. April 24, 2013. doi:10.1038/496397a. PMID 23627002.
  20. ^ Larson, Christina (April 10, 2013). "CDC Races to Create a Vaccine for China's Latest Bird Flu Strain". Bloomberg BusinessWeek. Retrieved June 7, 2020.
  21. ^ Prasad, R. (January 19, 2020). "What is the source of the new SARS-like disease reported in China?". The Hindu. Retrieved June 7, 2020.
  22. ^ Ng, Kang-chung (January 12, 2020). "Wuhan pneumonia: Hong Kong set to develop new test for mystery virus after obtaining genetic sequence from mainland China". South China Morning Post. Retrieved June 7, 2020.
  23. ^ "Epidemiological update: Monkeypox multi-country outbreak". www.ecdc.europa.eu. June 9, 2022. Retrieved March 25, 2023.
  24. ^ "70 years of GISRS – the Global Influenza Surveillance & Response System". World Health Organisation. Retrieved May 4, 2023.
  25. ^ a b Fidler, David P. (January 2008). "Influenza Virus Samples, International Law, and Global Health Diplomacy". Emerging Infectious Diseases. 14 (1): 88–94. doi:10.3201/eid1401.070700. PMC 2600156. PMID 18258086. S2CID 32706081.
  26. ^ Editorial (March 15, 2006). "Secret Avian Flu Archive". The New York Times. Archived from the original on April 4, 2023. Retrieved May 5, 2023.
  27. ^ a b Enserink, Martin (November 10, 2006). "Italy's Influenza Diva". Science. 314 (5801): 918–919. doi:10.1126/science.314.5801.918. PMID 17095672. S2CID 161378290.
  28. ^ a b c Enserink, Martin; Cohen, Jon (April 19, 2023). "The 'invented persona' behind a key pandemic database". Science. doi:10.1126/science.adi3224. Retrieved April 21, 2023.
  29. ^ a b Zamiska, Nicholas (August 30, 2006). "A Nonscientist Pushes Sharing Bird-Flu Data'". The Wall Street Journal. Archived from the original on March 27, 2023. Retrieved November 10, 2016.
  30. ^ a b Bogner, Peter; Capua, Ilaria; Lipman, David; Cox, Nancy (August 30, 2006). "A global initiative on sharing avian flu data". Nature. 442 (7106): 981. Bibcode:2006Natur.442Q.981B. doi:10.1038/442981a.
  31. ^ John Lauerman (August 25, 2006). "Poor countries may patent bird virus strains". Bloomberg News.
  32. ^ "Boosting access to disease data". Nature (Editorial). 442 (7106): 957. August 31, 2006. Bibcode:2006Natur.442Q.957.. doi:10.1038/442957a. PMID 16943803. S2CID 5320096.
  33. ^ McDowell, Robin (May 18, 2008). "Indonesia will add its data to global bird-flu Web site". Orlando Sentinel. Retrieved November 19, 2020. China, Russia and other nations that have long withheld influenza-virus samples and DNA-sequencing data from the international community are also taking part in the initiative, saying it offers full transparency and, for the first time, basic protection of intellectual-property rights.
  34. ^ Quirk, Mary (October 2006). "Non-WHO global initiative on sharing avian influenza data". The Lancet Infectious Diseases. 6 (10): 621. doi:10.1016/S1473-3099(06)70589-8.
  35. ^ Butler, Declan (December 2007). "Q&A: Siti Fadilah Supari". Nature. 450 (7173): 1137. Bibcode:2007Natur.450.1137B. doi:10.1038/4501137a. PMID 18097360. S2CID 4384824.
  36. ^ "Global flu database goes live" (PDF). FAOAIDEnews. May 16, 2008. p. 1. Retrieved May 5, 2023.
  37. ^ a b Butler, Declan (2009). "Flu database rocked by legal row". Nature. 460 (7257): 787. doi:10.1038/460786b. PMID 19675613.
  38. ^ Armstrong Moore, Elizabeth (September 16, 2009). "Launch of new flu database ruffles feathers". CNET. Retrieved May 5, 2023.
  39. ^ "Influenza pathogen database of global significance set up in Bonn". BMEL Homepage. April 15, 2010. Archived from the original on January 3, 2017. Retrieved January 2, 2017.
  40. ^ "Germany's Statement on Substantive Issues and Concerns Regarding the PIP Framework and its Implementation, Special Session of the PIP Advisory Group, October 13, 2015" (PDF). World Health Organization, Geneva. Retrieved November 8, 2016.
  41. ^ "GISAID Datenbank liefert grundlegende Informationen für Bekämpfungsstrategien" (PDF). BLE Homepage. April 16, 2014. Archived from the original (PDF) on January 3, 2017. Retrieved January 2, 2017.
  42. ^ "Weltweit größte Datenbank unterstützt Forschung an Grippeimpfstoffen". BMEL (in German). March 17, 2022. Retrieved April 7, 2023.
  43. ^ "Dispute simmers over who first shared SARS-CoV-2's genome". www.science.org. Retrieved March 29, 2023.
  44. ^ Ryan, Valerie (August 10, 2020). "SARS-CoV-2 virus strains circulating in Ireland identified". Irish Medical Times. Retrieved August 11, 2020.
  45. ^ Nasri, Ferdous; Kongkitimanon, Kunaphas; Wittig, Alice; Cortés, Jorge Sánchez; Brinkmann, Annika; Nitsche, Andreas; Schmachtenberg, Anna-Juliane; Renard, Bernhard Y.; Fuchs, Stephan (March 13, 2023). "MpoxRadar: a worldwide Mpox genomic surveillance dashboard". bioRxiv: 2023.02.03.526935. doi:10.1101/2023.02.03.526935. S2CID 256630934.
  46. ^ "GISAID - Submission Tracker Global RSV". gisaid.org. Retrieved March 28, 2023.
  47. ^ "Ministry establishes GISAID Academy for improving bioinformatics". Antara News. November 29, 2023.
  48. ^ LoTempio, Jonathan; Spencer, D'Andre; Yarvitz, Rebecca; Vilain, Arthur Delot; Vilain, Eric; Délot, Emmanuèle (August 19, 2020). "We Can Do Better: Lessons Learned on Data Sharing in COVID-19 Pandemic Can Inform Future Outbreak Preparedness and Response". Science & Diplomacy – via AAAS. GISAID further required that data users not only give credit to data submitters, but make maximum efforts to work with and include them in joint analyses on viral sequence data, further tipping the scales in favor of collaboration. This mandated sharing of not only data, but the benefits of research, has resulted in a paradigm shift which helps to put contributors from higher or lower resource settings on the same footing. ... Adopting a system of credit sharing similar to GISAID's would ensure that regardless of resource setting, data depositors are incentivized and recognized.
  49. ^ a b c d e f g Nuki, Paul (June 13, 2023). "This man created our best chance of stopping the next pandemic but now he is under attack. Why?". The Telegraph.
  50. ^ Maxmen, Amy (April 23, 2021). "One million coronavirus sequences: popular genome site hits mega milestone". Nature. More than 1.2 million coronavirus genome sequences from 172 countries and territories have now been shared on a popular online data platform
  51. ^ Press Trust of India (July 22, 2021). "OPrevalence of COVID-19's Delta variant among specimens sequenced over past 4 weeks exceeded 75%: WHO". The Hindu. as of July 20, a total of over 2.4 million SARS-CoV-2 sequences have been submitted to GISAID
  52. ^ Varela, Anna (November 16, 2021). "Georgia State Researchers Develop Rapid Computer Software To Track Pandemics As They Happen". GSU.edu. Georgia State University. Retrieved December 1, 2021.
  53. ^ Maxmen, Amy (December 16, 2021). "Omicron blindspots: why it's hard to track coronavirus variants". Nature. 600 (7890): 579. Bibcode:2021Natur.600..579M. doi:10.1038/d41586-021-03698-7. PMID 34916668. S2CID 245262198.
  54. ^ Sweeney, Lucy (January 8, 2023). "Could China's COVID-19 outbreak lead to the next variant of concern? Here's what the experts say". Australian Broadcasting Corp. Retrieved February 24, 2023.
  55. ^ Burki, Talha (April 2023). "First shared SARS-CoV-2 genome: GISAID vs virological.org". The Lancet Microbe. 4 (6): S2666524723001337. doi:10.1016/S2666-5247(23)00133-7. PMC 10129129. PMID 37116518.
  56. ^ Munnink, Bas (September 9, 2021). "The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology". Nature Medicine. 27 (9): 1518–1524. doi:10.1038/s41591-021-01472-w. PMID 34504335. S2CID 237468106. During the first year of the pandemic, a large number of SARS-CoV-2 whole-genome sequences were generated from all around the world and shared, mostly through GISAID.
  57. ^ Cocks, Tim (November 30, 2021). "How South African scientists spotted the Omicron COVID variant". Reuters. Retrieved December 1, 2021.
  58. ^ "Newly revealed coronavirus data has reignited a debate over the virus's origins". MIT Technology Review. Retrieved March 28, 2023.
  59. ^ Wu, Katherine J. (March 21, 2023). "A Major Clue to COVID's Origins Is Just Out of Reach". The Atlantic. Retrieved March 28, 2023.
  60. ^ "Unearthed genetic sequences from China market may point to animal origin of COVID-19". www.science.org. Retrieved March 28, 2023.
  61. ^ "WHO, advisors urge China to release all COVID-related data after new research". Reuters. March 19, 2023. Retrieved March 28, 2023.
  62. ^ "New genetic analysis finds clues to animal origin of COVID outbreak". www.cbsnews.com. March 17, 2023. Retrieved March 28, 2023.
  63. ^ Safi, Michael; Block, Eli (March 28, 2023). "'Being truthful is essential': scientist who stumbled upon Wuhan Covid data speaks out". The Guardian. ISSN 0261-3077. Retrieved March 28, 2023.
  64. ^ Mallapaty, Smriti (March 29, 2023). "COVID-origins report sparks debate over major genome hub GISAID". Nature. 616 (7955): 13–14. Bibcode:2023Natur.616...13M. doi:10.1038/d41586-023-00901-9. PMID 36991056. S2CID 257835687.
  65. ^ "GISAID - Governance". gisaid.org. Retrieved March 28, 2023.
  66. ^ a b "The 'invented persona' behind a key pandemic database". www.science.org. Retrieved April 21, 2023.
  67. ^ a b "A critical genetic database is under fire". The Economist. ISSN 0013-0613. Retrieved April 5, 2023.
  68. ^ a b Keymanthri Moodley; et al. (2022). "Ethics and governance challenges related to genomic data sharing in southern Africa: the case of SARS-CoV-2" (PDF). The Lancet. 10 (12): e1855–e1859. doi:10.1016/S2214-109X(22)00417-X. PMC 9826954. PMID 36309034.
  69. ^ "GISAID Database Access Agreement". www.gisaid.org. Retrieved May 8, 2020.
  70. ^ Lawson, Charles (October 7, 2016). "Open Access DNA, RNA and Amino Acid Sequences: The Consequences and Solutions for the International Regulation of Access and Benefit Sharing" (PDF). Journal of Law and Medicine. 24 (1): 96–118. PMID 30136777. Retrieved December 21, 2021.
  71. ^ a b Moodley, K; Cengiz, N; Domingo, A; Nair, G; Obasa, AE; Lessells, RJ; de Oliveira, T (December 2022). "Ethics and governance challenges related to genomic data sharing in southern Africa: the case of SARS-CoV-2". The Lancet. Global Health. 10 (12): e1855–e1859. doi:10.1016/S2214-109X(22)00417-X. PMC 9826954. PMID 36309034. S2CID 253165702.
  72. ^ a b Maxmen, Amy (May 13, 2021). "Why some researchers oppose unrestricted sharing of coronavirus genome data". Nature. 593 (7858): 176–177. Bibcode:2021Natur.593..176M. doi:10.1038/d41586-021-01194-6. PMID 33953391. S2CID 233867611.
  73. ^ Zuiderwijk, Anneke; Janssen, Marijn; Choenni, Sunil; Meijer, Ronald; Alibaks, Roexsana Sheikh (December 1, 2012). "Socio‑technical Impediments of Open Data". Electronic Journal of E-Government. 10 (2): 156–172. ISSN 1479-439X. Retrieved August 30, 2023.
  74. ^ "GISAID - FAQ". gisaid.org.
  75. ^ Kryukov, K; Jin, L; Nakagawa, S (September 9, 2022). "Efficient compression of SARS-CoV-2 genome data using Nucleotide Archival Format". Patterns (New York, N.Y.). 3 (9): 100562. doi:10.1016/j.patter.2022.100562. PMC 9259476. PMID 35818472.
  76. ^ Bernasconi, A; Canakoglu, A; Masseroli, M; Pinoli, P; Ceri, S (March 22, 2021). "A review on viral data sources and search systems for perspective mitigation of COVID-19". Briefings in Bioinformatics. 22 (2): 664–675. doi:10.1093/bib/bbaa359. PMC 7799334. PMID 33348368.
  77. ^ a b Van Noorden, Richard (February 11, 2021). "Scientists call for fully open sharing of coronavirus genome data". Nature. 590 (7845): 195–196. Bibcode:2021Natur.590..195V. doi:10.1038/d41586-021-00305-7. PMID 33542487. S2CID 231817576.
  78. ^ "Open letter: Support data sharing for COVID-19". www.covid19dataportal.org. Retrieved April 21, 2023.
  79. ^ "GISAID - Editorial Board affirms Open Access designation of GISAID". gisaid.org. Retrieved March 27, 2023.
  80. ^ Cohen, J (March 24, 2023). "New clues to pandemic's origin surface, causing uproar". Science. 379 (6638): 1175–1176. Bibcode:2023Sci...379.1175C. doi:10.1126/science.adh9055. PMID 36952417. S2CID 257696101. Retrieved March 27, 2023.
  81. ^ Wu, Katherine J. (March 21, 2023). "A Major Clue to COVID's Origins Is Just Out of Reach". The Atlantic. Retrieved March 27, 2023.
  82. ^ "GISAID | re3data.org". www.re3data.org. Retrieved March 27, 2023.
  83. ^ "Open letter: Support data sharing for COVID-19". www.covid19dataportal.org. COVID-19 Data Portal. Retrieved March 27, 2023.
  84. ^ Van Noorden, Richard (February 11, 2021). "Scientists call for fully open sharing of coronavirus genome data". Nature. 590 (7845): 195–196. Bibcode:2021Natur.590..195V. doi:10.1038/d41586-021-00305-7. PMID 33542487. S2CID 231817576.
  85. ^ Elbe, Stefan; Buckland-Merrett, Gemma (January 2017). "Data, disease and diplomacy: GISAID's innovative contribution to global health: Data, Disease and Diplomacy". Global Challenges. 1 (1): 33–46. Bibcode:2017GloCh...1...33E. doi:10.1002/gch2.1018. PMC 6607375. PMID 31565258. S2CID 15830721. According to GISAID, the percentage of all active users whose access credentials to the GISAID platform have been revoked at the time of writing is around 0.16%.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=GISAID&oldid=1262075838"